Romidepsin is also a class I selective HDAC inhibitor [18, 19], but it is already FDA-approved for treatment of cutaneous T-cell lymphoma (CTCL) with no reported pulmonary toxicity [20, 21]. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.